SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-020594
Filing Date
2022-08-03
Accepted
2022-08-03 16:07:30
Documents
59
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20220630.htm   iXBRL 10-Q 1415997
2 EX-10.1 mirati-lstelzercfoofferlet.htm EX-10.1 96812
3 EX-31.1 mrtx-2022630xex311.htm EX-31.1 14088
4 EX-31.2 mrtx-2022630xex312.htm EX-31.2 14960
5 EX-32.1 mrtx-2022630xex321.htm EX-32.1 7741
11 image_1a.jpg GRAPHIC 7858
  Complete submission text file 0001628280-22-020594.txt   5673597

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20220630.xsd EX-101.SCH 36042
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20220630_cal.xml EX-101.CAL 50816
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20220630_def.xml EX-101.DEF 150259
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20220630_lab.xml EX-101.LAB 440601
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20220630_pre.xml EX-101.PRE 269015
53 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20220630_htm.xml XML 912422
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 221132591
SIC: 2834 Pharmaceutical Preparations